Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of equity and Trading update

5 Apr 2011 07:00

5 April 2011 Cubus Lux plc ("Cubus Lux" or the "Company") Issue of equity and Trading update

The Company announces that it has allotted and issued 1,002,992 new ordinary shares of 10p each (the "Placing Shares") at 14p per share. Of these Placing Shares, 400,000 were issued by way of subscription for cash raising £56,000 and the remaining 602,992 were in lieu of an outstanding loan. The funds raised will be used to provide additional short term working capital for the Company.

The Placing Shares represent 3.85 per cent. of the Company's enlarged ordinary share capital. Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM ("Admission"). It is expected that such Admission will occur at 8.00 am on 8 April 2011.

Further to the half-yearly report dated 22 December 2010 the directors announce a trading and financing update as at the year-end of 31 March 2011.

Despite lengthy negotiations and due diligence to conclude a sale of the Casino business discussions remain ongoing and whilst the directors continue to believe that a sale will occur in due course, there is no immediate certainty as to when it will complete. In the meantime and whilst the Casino has undertaken a refurbishment, the Casino has not generated any revenues of note since the half year and will be significantly behind the revenues for the year-ended 31 March 2010.

The marina business has continued to trade steadily but revenues for the year are likely to come in behind budget and those of the previous financial year. Along with other incidental revenues the directors therefore anticipate revenues for the overall Group will be below those of the previous year. As part of the Company's divestment plans it is also considering the sale of the marina business and has had some preliminary discussions with a view to a sale.

As announced previously the Company's business of acquiring and developing various property projects, such as the Olive Island Resort and Valdanos, are contingent on procuring significant funding. The directors are optimistic that a funding solution will be resolved in the near term but, whilst the issue of the Placing shares will assist with short term working capital requirements for the Company, in the absence of any material funding the directors will be reviewing the ongoing liquidity of the Company closely over the coming few months.

Following the issue of the Placing Shares, the Company will have an issued share capital of 26,063,404 ordinary shares of 10p each. As the Company does not hold any ordinary shares in Treasury its total number of voting rights equals its capital. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.

For further information about the Company please see www.cubuslux.com orcontact:Cubus Lux plc Steve McCann +44 (0) 7787 183 184 Northland Capital Partners Luke Cairns/Rod Venables +44 (0) 20 7492 4750 (Nominated Adviser) Hybridan LLP Claire Noyce +44 (0) 20 7947 4350 (Broker)

vendor
Date   Source Headline
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 202211:00 amRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSDirectorate change
14th Mar 20224:41 pmRNSSecond Price Monitoring Extn
14th Mar 20224:36 pmRNSPrice Monitoring Extension
14th Mar 20222:05 pmRNSSecond Price Monitoring Extn
14th Mar 20222:00 pmRNSPrice Monitoring Extension
14th Mar 20227:00 amRNSLaunch of outdoor marketing campaign
8th Mar 202211:03 amRNSShare purchase by CEO
7th Mar 202211:05 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
4th Mar 20224:41 pmRNSSecond Price Monitoring Extn
4th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSExercise of Warrants
1st Mar 20227:00 amRNSLaunch of Rejuvenating Cannabinoid Face Serum
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
21st Feb 202211:05 amRNSSecond Price Monitoring Extn
21st Feb 202211:00 amRNSPrice Monitoring Extension
21st Feb 20229:05 amRNSSecond Price Monitoring Extn
21st Feb 20229:00 amRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSStrategy and trading update
2nd Feb 20227:00 amRNSWhite paper on cannabinoids and skin aging
7th Jan 20221:00 pmRNSResults of Annual General Meeting
15th Dec 20217:00 amRNSAnnual General Meeting update
8th Dec 20217:00 amRNSGrant of Options to CEO
6th Dec 20211:57 pmRNSPosting of Annual Report and Notice of AGM
6th Dec 20217:00 amRNSAppointment of new CEO
3rd Dec 20217:00 amRNSAnnual results
1st Dec 20217:00 amRNSLaunch of inaugural products & ecommerce platform
11th Nov 20217:00 amRNSAdvertising and PR agencies appointed
8th Nov 20212:05 pmRNSSecond Price Monitoring Extn
8th Nov 20212:00 pmRNSPrice Monitoring Extension
8th Nov 202111:05 amRNSSecond Price Monitoring Extn
8th Nov 202111:00 amRNSPrice Monitoring Extension
1st Nov 20217:00 amRNSGrant of Share Options and update on warrants
4th Oct 20219:06 amRNSSecond Price Monitoring Extn
4th Oct 20219:00 amRNSPrice Monitoring Extension
4th Oct 20217:00 amRNSDirector dealings & TR1 notification
16th Aug 20217:00 amRNSSupply agreement signed with Chanelle McCoy Health
2nd Aug 20217:00 amRNSShare disposal by significant shareholder
28th Jul 20212:06 pmRNSSecond Price Monitoring Extn
28th Jul 20212:00 pmRNSPrice Monitoring Extension
10th Jun 20217:00 amRNSSupply agreement signed with Willow Biosciences
25th May 20217:00 amRNSCellular Goods Interim Results
6th May 20217:00 amRNSGrant of Warrants and Extension of Exercise Period
20th Apr 20212:00 pmRNSPrice Monitoring Extension
12th Apr 20217:00 amRNSCellular Goods boosts team with five appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.